Krsnaa Diagnostics Limited (NSE: KRSNAA)
India
· Delayed Price · Currency is INR | Market Cap | 31.66B |
| Revenue (ttm) | 6.81B |
| Net Income (ttm) | 692.15M |
| Shares Out | 32.29M |
| EPS (ttm) | 20.94 |
| PE Ratio | 46.83 |
| Forward PE | 31.16 |
| Dividend | 2.50 (0.25%) |
| Ex-Dividend Date | Sep 13, 2024 |
| Volume | 55,726 |
| Open | 1,014.25 |
| Previous Close | 1,006.55 |
| Day's Range | 993.00 - 1,015.00 |
| 52-Week Range | 528.05 - 1,044.00 |
| Beta | -0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About Krsnaa Diagnostics
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers various diagnostic services, including radiology, pathology, and teleradiology services. The company also provides health packages, such as diagnostic testing packages for diabetes, heart health, liver health, kidney health, thyroid, fatigue, cancer, senior citizen care, bone health, infection screening, fever profiles, etc. It serves its services to public and private hospitals, medical colleges, and community health centers. Krsnaa Diagnostics Limited was incorporated... [Read more]
Financial Performance
In 2023, Krsnaa Diagnostics's revenue was 6.20 billion, an increase of 27.20% compared to the previous year's 4.87 billion. Earnings were 568.37 million, a decrease of -8.49%.
Financial StatementsNews
Lab stops blood collection at 400 BMC hosps over pending dues
Krsnaa Diagnostics has suspended blood collection services at over 400 civic hospitals in Mumbai due to overdue payments totaling nearly Rs 10 crore, leaving patients in distress and hospitals in chao...
Krsnaa Diagnostics shares surge nearly 6% as Q2 net sales reach ₹186.34 crore
Krsnaa Diagnostics, a small-cap company in the healthcare services industry, has reported a solid financial performance for the second quarter of FY25. The company’s net sales reached ₹186.34 crore, m...
Stock in Focus: Krsnaa Diagnostics secures two major agreements in Ranchi
Krsnaa Diagnostics announced it has secured agreements with the Ranchi Institute of Neuro-Psychiatry & Allied Services (RINPAS) and Sadar Hospital, Ranchi. These public-private partnerships involve se...
Krsnaa Diagnostics to acquire 24% stake in start-up Apulki Healthcare
Krsnaa Diagnostics plans to acquire a 24% stake in Apulki Healthcare, securing exclusive rights to provide diagnostic services at Apulki's oncology and cardiology hospitals. This partnership will ensu...
Krsnaa Diagnostics secures radiology services contract at Sadar Hospital, Ranchi
Krsnaa Diagnostics Limited has been awarded a Letter of Intent (LOI) by Sadar Hospital, Ranchi, Jharkhand, to establish a Public-Private Partnership (PPP) project. This contract involves commissioning...
Krsnaa Diagnostics acquires stake in India’s first PPP cancer and cardiac care hospitals
Krsnaa Diagnostics Ltd, one of India’s leading integrated diagnostic service providers, has made a strategic investment in Apulki Healthcare Private Limited, the country’s first Public-Private Partner...
Krsnaa Diagnostics share price surges over 3% after company agrees to acquire 23.53% stake in Apulki Healthcare
Krsnaa Diagnostics shares jumped more than 3% in morning trade after the company agreed to acquire 23.53% stake in Apulki Healthcare Private Limited. Krsnaa Diagnostics Limited will pay a cash conside...